Results for:(124 found)
Jun 14, 2013 1:45PM on Top StocksBy StreetAuthority

The regulator has created an accelerated path to market for the most promising drugs -- and these health giants stand to gain the most.

Tags: MRKNVSPFE
Jun 10, 2013 4:44PM on Top StocksBy StreetAuthority

This sector has been back in vogue, but investors could miss out on further upside without careful stock selection.

Jun 3, 2013 3:59PM on Top StocksBy Motley Fool Investor Beat

In this installment of Investor Beat: is the run over for dividend stocks if the Fed changes course?

Jun 3, 2013 3:15PM on Top StocksBy MSN Money Partner

Stocks are mixed as the Dow and S&P 500 have gained, but the tech-heavy Nasdaq is lagging.

May 30, 2013 11:54AM on Top StocksBy MSN Money Partner

Halliburton is downgraded to 'underweight,' and Eli Lilly is initiated with a 'buy.'

May 28, 2013 12:05PM on Top StocksBy MSN Money Partner

Exelon is downgraded to 'hold,' and Jabil Circuit is initiated with a 'buy.'

May 9, 2013 4:21PM on Top StocksBy Money Staff

Share buybacks can boost stock prices. Here are the 10 biggest so far this year.

May 3, 2013 9:08AM on Top StocksBy Jim Cramer

Unlike biotechs, many of these companies are pouring money into share buybacks -- instead of their long-term pipelines.

VIDEO ON MSN MONEY

DATA PROVIDERS

Copyright © 2014 Microsoft. All rights reserved.

Fundamental company data and historical chart data provided by Morningstar Inc. Real-time index quotes and delayed quotes supplied by Morningstar Inc. Quotes delayed by up to 15 minutes, except where indicated otherwise. Fund summary, fund performance and dividend data provided by Morningstar Inc. Analyst recommendations provided by Zacks Investment Research. StockScouter data provided by Verus Analytics. IPO data provided by Hoover's Inc. Index membership data provided by Morningstar Inc.

MARKET DISPATCHES

No more Dispatches; here's where to find market news

The Market Dispatches column has been discontinued. Here's where to find the latest stock and business news on MSN Money, and the latest from market writer Charley Blaine.

More